Pamela Vig - Jun 24, 2024 Form 4 Insider Report for Mirum Pharmaceuticals, Inc. (MIRM)

Signature
/s/ Judit Ryvkin, Attorney-in-Fact
Stock symbol
MIRM
Transactions as of
Jun 24, 2024
Transactions value $
-$949,285
Form type
4
Date filed
6/25/2024, 05:15 PM
Previous filing
May 16, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MIRM Common Stock Options Exercise $89.7K +30.6K +111.5% $2.94 58K Jun 24, 2024 Direct
transaction MIRM Common Stock Sale -$1.04M -30.6K -52.72% $34.00 27.4K Jun 24, 2024 Direct F1
holding MIRM Common Stock 75K Jun 24, 2024 By The Vig-Ancock Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MIRM Stock Option (right to buy) Options Exercise $0 -30.6K -19.56% $0.00 126K Jun 24, 2024 Common Stock 30.6K $2.94 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted in March 2024.
F2 The stock option is fully vested.